On the stock market since 2022, it operates in the world of health and science. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $85.8M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 12 months, company executives reported 55 buys and 3 sells. Management buying with its own money is usually read as a good sign.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, BTMDW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BTMDW is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.